Showing 4321-4330 of 5646 results for "".
- Hydrus Microstent Lowers Visual Field Loss by 47%, According to New 5-Year Pivotal Trial Datahttps://modernod.com/news/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data/2480443/Ivantis, developer of the Hydrus Microstent, announced new data from its 5-year HORIZON t
- CORD LLC Completes One-Year Follow-Up on Subjects From the Model SC9 Intraocular Lens FDA Clinical Trialhttps://modernod.com/news/cord-llc-completes-one-year-follow-up-on-subjects-from-the-model-sc9-intraocular-lens-fda-clinical-trial/2480435/Cumming Ophthalmic Research and Development
- iSTAR Medical Present Final Results From STAR-II European Trial for MINIject in Glaucoma Patients at AAOhttps://modernod.com/news/istar-medical-present-final-results-from-star-ii-european-trial-for-miniject-in-glaucoma-patients-at-aao/2480433/iSTAR Medical announced final results of the STAR-II European trial for its MIGS device, MINIject. These data show consistently outstanding performance and a favorable safety profile in patients with primary open-angle glaucoma up to 2 years of follow-up. The trial results will be presented at th
- Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Diseasehttps://modernod.com/news/opus-genetics-announces-agreement-with-massachusetts-eye-and-ear-and-harvard-medical-school-to-license-third-program-for-inherited-retinal-disease/2480431/Opus Genetics, a gene therapy company developing treatments for orphan inherited retinal diseases, announced an agreement to license its third preclinical program to address mutations in the NMNAT1 gene, which cause a specific form of Leber congenital amaurosis (LCA), from Massa
- LumiThera Acquires Diopsys, Provider of Light-Based Theranostic Approach to Treat Ocular Diseasehttps://modernod.com/news/lumithera-acquires-diopsys-provider-of-light-based-theranostic-approach-to-treat-ocular-disease/2480430/LumiThera announced its entry into a definitive merger agreement with Diopsys, a provider of modern visual electrophysiology medical devices that help eye care professionals analyze the entire visual pathway for visual and neuro-visual disorders. Under the terms of
- Ziemer USA Announces Partnership With CorneaGenhttps://modernod.com/news/ziemer-usa-announces-partnership-with-corneagen/2480429/Ziemer USA, a wholly owned subsidiary of Switzerland-based Ziemer AG, announced a new partnership with CorneaGen. "We have started an exciting new collaboration with CorneaGen," said David Bragg, President of Ziemer USA & Canada. "Through combined developme
- Abbvie and Regenxbio Announce Collaboration to Advance Gene Therapy for Retinal Diseaseshttps://modernod.com/news/abbvie-and-regenxbio-announce-collaboration-to-advance-gene-therapy-for-retinal-diseases/2480427/AbbVie and Regenxbio announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in
- Oyster Point Pharma to Present Data at the American Academy of Ophthalmology Annual Meeting 2021https://modernod.com/news/oyster-point-pharma-to-present-data-at-the-american-academy-of-ophthalmology-annual-meeting-2021/2480417/Oyster Point Pharma announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) annual meeting 2021 being held in New Orleans, November 12–15, 2021. “The American Academy of Ophthalmology is the world’
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- Prism Vision Group Acquires Three New Practiceshttps://modernod.com/news/prism-vision-group-acquires-three-new-practices/2480398/PRISM Vision Group announced that it has recently acquired Bethlehem Eye Associates in Bethlehem, Pennsylvania; Schefkind Eye Care with two locations in Alexandria, Virginia; and Carabin Eye Care in New Milford, New Jersey. Terms of the deals were not disclosed.